140 related articles for article (PubMed ID: 37327713)
1. Treatment and outcomes of symptomatic hyperammonemia following asparaginase therapy in children with acute lymphoblastic leukemia.
Lee A; Eldem I; Altintas B; Nguyen H; Willis D; Langley R; Shinawi M
Mol Genet Metab; 2023 Jul; 139(3):107627. PubMed ID: 37327713
[TBL] [Abstract][Full Text] [Related]
2. Hyperammonemia secondary to asparaginase: A case series.
Nussbaum V; Lubcke N; Findlay R
J Oncol Pharm Pract; 2016 Feb; 22(1):161-4. PubMed ID: 25245038
[TBL] [Abstract][Full Text] [Related]
3. [Molecular basis of hyperammonemia secondary to asparaginase: from therapeutic efficacity to toxicity].
Gallin M; Damaj L; Gandemer V; Bendavid C; Moreau C
Ann Biol Clin (Paris); 2023 Oct; 81(4):365-377. PubMed ID: 37864442
[TBL] [Abstract][Full Text] [Related]
4. Multiple Asparaginase Infusions Cause Increasingly Severe Acute Hyperammonemia.
Buddington RK; Buddington KK; Howard SC
Med Sci (Basel); 2022 Aug; 10(3):. PubMed ID: 35997335
[TBL] [Abstract][Full Text] [Related]
5. Transient hyperammonemia due to L-asparaginase therapy in children with acute lymphoblastic leukemia or non-Hodgkin lymphoma.
Jörck C; Kiess W; Weigel JF; Mütze U; Bierbach U; Beblo S
Pediatr Hematol Oncol; 2011 Feb; 28(1):3-9. PubMed ID: 20615069
[TBL] [Abstract][Full Text] [Related]
6. Pharmacotherapies that specifically target ammonia for the prevention and treatment of hepatic encephalopathy in adults with cirrhosis.
Zacharias HD; Zacharias AP; Gluud LL; Morgan MY
Cochrane Database Syst Rev; 2019 Jun; 6(6):CD012334. PubMed ID: 31204790
[TBL] [Abstract][Full Text] [Related]
7. Symptomatic hyperammonemia secondary to recombinant Erwinia asparaginase.
Martin CE; Kohorst MA; Ferdjallah A; Kalmes JL; Johnson HM; Galardy PJ; Khan SP; Kuhn AK
Pediatr Blood Cancer; 2023 May; 70(5):e30208. PubMed ID: 36633209
[No Abstract] [Full Text] [Related]
8. Symptomatic Hyperammonemia With Erwinia chrysanthemi-derived Asparaginase in Pediatric Leukemia Patients.
Gossai N; Richards M; Boman L; Messinger Y; Gernbacher S; Perkins J; Bostrom B
J Pediatr Hematol Oncol; 2018 May; 40(4):312-315. PubMed ID: 29334534
[TBL] [Abstract][Full Text] [Related]
9. The toxicity of very prolonged courses of PEGasparaginase or Erwinia asparaginase in relation to asparaginase activity, with a special focus on dyslipidemia.
Tong WH; Pieters R; de Groot-Kruseman HA; Hop WC; Boos J; Tissing WJ; van der Sluis IM
Haematologica; 2014 Nov; 99(11):1716-21. PubMed ID: 25150254
[TBL] [Abstract][Full Text] [Related]
10. Ammonia level as a proxy of asparaginase inactivation in children: A strategy for classification of infusion reactions.
Santos AC; Land MGP; Lima EC
J Oncol Pharm Pract; 2022 Apr; 28(3):551-559. PubMed ID: 33645327
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of immunologic crossreaction of antiasparaginase antibodies in acute lymphoblastic leukemia (ALL) and lymphoma patients.
Wang B; Relling MV; Storm MC; Woo MH; Ribeiro R; Pui CH; Hak LJ
Leukemia; 2003 Aug; 17(8):1583-8. PubMed ID: 12886246
[TBL] [Abstract][Full Text] [Related]
12. Recombinant Erwinia asparaginase (JZP458) in acute lymphoblastic leukemia: results from the phase 2/3 AALL1931 study.
Maese L; Loh ML; Choi MR; Lin T; Aoki E; Zanette M; Agarwal S; Iannone R; Silverman JA; Silverman LB; Raetz EA; Rau RE
Blood; 2023 Feb; 141(7):704-712. PubMed ID: 36108304
[TBL] [Abstract][Full Text] [Related]
13. High incidence of symptomatic hyperammonemia in children with acute lymphoblastic leukemia receiving pegylated asparaginase.
Heitink-Pollé KM; Prinsen BH; de Koning TJ; van Hasselt PM; Bierings MB
JIMD Rep; 2013; 7():103-8. PubMed ID: 23430503
[TBL] [Abstract][Full Text] [Related]
14. Outcome of pediatric patients with acute lymphoblastic leukemia/lymphoblastic lymphoma with hypersensitivity to pegaspargase treated with PEGylated Erwinia asparaginase, pegcrisantaspase: A report from the Children's Oncology Group.
Rau RE; Dreyer Z; Choi MR; Liang W; Skowronski R; Allamneni KP; Devidas M; Raetz EA; Adamson PC; Blaney SM; Loh ML; Hunger SP
Pediatr Blood Cancer; 2018 Mar; 65(3):. PubMed ID: 29090524
[TBL] [Abstract][Full Text] [Related]
15. A comprehensive strategy to address shortage of Erwinia asparaginase in pediatric acute lymphoblastic leukemia.
Vagrecha A; Tao V; Corless R; Colon C; Redner A; Atlas M
Expert Rev Clin Pharmacol; 2023; 16(8):763-769. PubMed ID: 37294084
[TBL] [Abstract][Full Text] [Related]
16. The use of Erwinia asparaginase for adult patients with acute lymphoblastic leukemia after pegaspargase intolerance.
Horvat TZ; Pecoraro JJ; Daley RJ; Buie LW; King AC; Rampal RK; Tallman MS; Park JH; Douer D
Leuk Res; 2016 Nov; 50():17-20. PubMed ID: 27631159
[TBL] [Abstract][Full Text] [Related]
17. Hypersensitivity reactions to asparaginase therapy in acute lymphoblastic leukemia: immunology and clinical consequences.
Burke MJ; Zalewska-Szewczyk B
Future Oncol; 2022 Mar; 18(10):1285-1299. PubMed ID: 35107320
[TBL] [Abstract][Full Text] [Related]
18. Optimizing asparaginase therapy for acute lymphoblastic leukemia.
Rizzari C; Conter V; Starý J; Colombini A; Moericke A; Schrappe M
Curr Opin Oncol; 2013 Mar; 25 Suppl 1():S1-9. PubMed ID: 23380829
[TBL] [Abstract][Full Text] [Related]
19. Incidence and management of asparaginase-associated adverse events in patients with acute lymphoblastic leukemia.
Earl M
Clin Adv Hematol Oncol; 2009 Sep; 7(9):600-6. PubMed ID: 20020672
[TBL] [Abstract][Full Text] [Related]
20. Asparaginase
Gao C; Ma X; Zhang Z; Lu Q; Ashby CR; Wei L; Chen ZS
Drugs Today (Barc); 2022 Jun; 58(6):261-271. PubMed ID: 35670704
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
